Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China rights to Zelgen’s lead oncology asset, alvetamig (ZG-006), a trispecific T-cell engager targeting delta-like ligand 3 (DLL3). Under terms of the deal, Abbvie will pay Zelgen an up-front fee of $100 million, and Zelgen is eligible to receive $60 million in near-term milestones and could receive up to $1.075 billion in additional development, regulatory and commercial milestones, alongside tiered royalties on net sales outside China. Zelgen retains full rights in China. Alveltamig is a next-generation, trispecific antibody designed to engage T cells while targeting DLL3, a protein that has re-emerged as a focal point in oncology following renewed interest in T-cell engager and multispecific antibody approaches after earlier antibody-drug conjugate strategies struggled with safety and durability.
Missed window? A third CRL sinks Outlook’s ONS-5010
Receiving a third complete response letter (CRL) from the U.S. FDA for its bevacizumab formulation, ONS-5010, to treat wet age-related macular degeneration, Outlook Therapeutics Inc. watched its stock (NASDAQ:OTLK) plummet 58% in early trading Jan. 2 to just 67 cents each. “Unfortunately, the window of opportunity may have passed,” said H.C. Wainwright analyst Douglas Tsao, who noted that recent approvals in Europe may not provide enough capital within the company’s existing runway.
Psithera spun out of Roivant with $47.5M to develop small molecules for immune and inflammatory targets
December 2025 was a big month for announcements from Psithera Inc. The newco changed its name from Psivant Therapeutics, came out from under the Roivant Sciences Ltd. umbrella – thus the dropping of the -vant name – announced a $47.5 million series A financing and appointed Eric Shaff as its new CEO. BioWorld checks in on what the company has been doing with its Quaisar platform since Roivant inherited the computational intelligence technology through its 2021 acquisition of Silicon Therapeutics LLC.
ADCs’ breakout 2025 and their still-unfinished potential
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was reported, with innovations spanning targets, linkers, payloads, conjugation chemistries and overall architectures. Once defined by a simple “one target, one payload” model, the field is lately expanding into a more versatile and diverse therapeutic space. Data from Clarivate’s Cortellis Drug Discovery & Intelligence estimates that ADCs generated $13.55 billion in 2024, a figure projected to grow to $16 billion in 2025.
Holiday notice
BioWorld's offices were closed Thursday, Jan. 1. No issue was published.
BioWorld 2025 Year in Review
BioWorld looks back at the year’s biggest news. Find all of our 2025 Year in Review articles here.
Also in the news
Arbormed, Axsome, Bioatla, Corcept, Cybin, Emmaus, Gatc, Hyloris, Insilico, Mabwell, Neoimmunetech, Novo Nordisk, Ultragenyx, Vanda
Notice of email fulfillment change
Effective Jan. 5, 2026, BioWorld is switching email fulfillment services. While we have made every effort to ensure that all current user subscription details — as well as information on users who have unsubscribed — have been migrated accurately to the new system, there may be a few instances where certain information may not have carried over as expected. If you have any concerns that you received a newsletter in error or if a colleague has not received an expected newsletter, do not hesitate to reach out to our customer care team. You can submit a query. Or call us:
- Americas: 855-258-3279
- Europe, Middle East, and Africa: +44 8081 963232
Going forward, if you would like to be unsubscribed, click on the ‘Unsubscribe’ link at the bottom of the emailed newsletter.